{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The A30P mutation accelerates nucleation-dependent fibrillization of wild type α-synuclein and affects the conformation and fibrillization of both WT and A30P, which may explain its association with Parkinson disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to the effect of A30P on fibrillization and its role in Parkinson disease pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses nucleation-dependent fibrillization assays and electron microscopy to assess the effect of A30P on α-synuclein fibrillization.",
          "judgment": "Yes",
          "reasoning": "The assays used effectively model the disease pathogenesis by demonstrating the impact of A30P on fibrillization, a key process in Parkinson disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study includes WT α-synuclein as a normal control and mutant α-synuclein variants as abnormal controls, with experiments performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "Both normal and abnormal controls are used, and experiments are replicated, meeting the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study uses known pathogenic variants (A53T, E46K) as controls in the assays.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants are used as controls, allowing for a robust comparison and validation of the A30P variant's effect.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper does not provide specific statistical analyses or OddsPath calculations.",
          "judgment": "No",
          "reasoning": "The paper lacks detailed statistical analyses necessary to calculate OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study uses at least three pathogenic variant controls (A53T, E46K, WT) in the assays.",
          "judgment": "Yes",
          "reasoning": "The presence of multiple pathogenic controls supports a moderate level of functional evidence.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The A30P variant shows a moderate level of pathogenic evidence due to its significant effect on fibrillization and the use of multiple pathogenic controls, despite the lack of detailed statistical analyses."
    }
  ]
}
